Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 4,270 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood samples collected Clear all
Recruiting No phase listed Observational

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

NCT05530759
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Specimen, Biospecimen Collection, Archived Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting Phase 1 Interventional

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT05943496
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Obinutuzumab, Questionnaire Administration, Tafasitamab
Drug · Procedure · Biological + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational

Tissue Immune Interaction in Nasal Polyposis

NCT04628442
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Sinonasal Debridement Procedure, Nasal Polyp Removal, Biopsy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 29, 2026, 2:35 AM EDT
Active, not recruiting Phase 1 Interventional

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01251874
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography, Veliparib
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetics Of Autoimmunity In Type I Diabetes

NCT03648918
View directory record Official record
Conditions
Type1diabetes, Diabetes Mellitus, Type 1, Type1 Diabetes Mellitus, Diabetes Mellitus
Interventions
Blood Collection
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2050
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease

NCT03136679
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Molecular Genetics Studies of Cancer Patients and Their Relatives

NCT04185935
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Biospecimen Collection, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2033
U.S. locations
35
States / cities
Phoenix, Arizona • Concord, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transfusion of Older Stored Red Cells

NCT01534676
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Transfusion, Blood, Chelation therapy
Procedure · Biological
Lead sponsor
Columbia University
Other
Eligibility
1 Year to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 29, 2026, 2:35 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

NCT04291950
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsy
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars

NCT00700791
View directory record Official record
Conditions
Scar
Interventions
Natural Vitamin E Tocotrienol supplement (TCT), Natural Vitamin E Tocotrienol Cream (TCT), Placebo, Placebo Cream
Dietary Supplement · Device · Other
Lead sponsor
Chandan K Sen
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 29, 2026, 2:35 AM EDT
Not yet recruiting Phase 1 Interventional

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

NCT07729397
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-Negative
Interventions
Autologous C7R.CD30-CAR-EBVSTs
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
16 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational Results available

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

NCT01099397
View directory record Official record
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated Not applicable Interventional

Treatment of Multifocal Lung Adenocarcinoma

NCT01946100
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma Non-small-cell Lung, Adenocarcinoma
Interventions
Multifocal Lung Adenocarcinoma
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 29, 2026, 2:35 AM EDT
Withdrawn Phase 2 Interventional

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

NCT07062016
View directory record Official record
Conditions
Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00482352
View directory record Official record
Conditions
Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
11,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
176
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 29, 2026, 2:35 AM EDT
Withdrawn Early Phase 1 Interventional

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

NCT04051047
View directory record Official record
Conditions
Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma, Glioma
Interventions
Gemcitabine, Tumor biopsy and blood draw
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

NCT05837455
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Data Collection Study Using CS (CardiacSense) BP (Blood Pressure) Watch and Pillow Systems

NCT07749963
View directory record Official record
Conditions
Blood Pressure Monitoring
Interventions
CS BP Watch and CS BP Pillow Systems
Device
Lead sponsor
CardiacSense Ltd.
Industry
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

NCT00648414
View directory record Official record
Conditions
Healthy
Interventions
Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

NCT07460752
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Goserelin Acetate, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

NCT03141684
View directory record Official record
Conditions
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
42
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy

NCT01100398
View directory record Official record
Conditions
Fatty Liver
Interventions
possible liver biopsy and serum collection
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2010 · Synced Oct 29, 2026, 2:35 AM EDT